

ACCESS TO PRECISION CANCER MEDICINE (PCM) IN NORWAY

Meeting Agenda

Increasing levels of precision in cancer treatment challenge the current access pathways. As patient populations become smaller, the evidence becomes more limited, putting strain on traditional regulatory and reimbursement models. The discussion will focus on how Norway can leverage outcomes from EU initiatives, cross-border trial evidence, and evolving access frameworks to overcome the structural barriers and ensure that advances in PCM translate into better and equitable care for cancer patients.

Date: 12.05.26
Time: Kl 11.30 - 16.00
Location: Kreftforeningens Vitensenter
Address: Kongens gate 6, 0153 Oslo

From 11:30 | Welcome to lunch

Introductory session

12.00 - 12.35

Welcome remarks

- Cancer Mission Hub Norway, **Ingrid Stenstadvold Ross**, Secretary General, Norwegian Cancer Society (5min)
- ECHoS, **Yasmin Fonseca**, Project Manager (5min)
- The European Observatory on Health Systems and Policies, **Florian Tille**, Technical Officer (5min)
- CONNECT - The Norwegian Cancer Precision Medicine Implementation Consortium, **Knut Martin Torgersen**, Project Leader (5min)
- Tour de table participants (10min)

Setting the stage: what is holding us back?

12.35 - 13.10

Perspectives from

- **Prof. Mark Lawler**, Associate Pro-Vice-Chancellor, Professor of Digital Health, and Chair in Translational Cancer Genomics, Faculty of Medicine, Health and Life Sciences, Queen's University Belfast (online)
- **Prof. Kjetil Taskén**, Professor of Medicine, University of Oslo, Head of the Institute for Cancer Research, Oslo University Hospital

Cross-border clinical trials: strengthening evidence, expanding access

13.10 - 14.10 | **Moderator:** Florian Tille, the European Observatory on Health Systems and Policies

Framing the dialogue: Sigrid Bratlie, Strategic Advisor, Norwegian Cancer Society (5min)

Guiding topics for discussion:

- *Expanding access to PCM trials across borders: towards EU operating as a joint clinical trial region?*
- *Building joint cohorts and shared trial infrastructure*
- *Designing PCM trial protocols for HTA from the start*

14.10 - 14.40 | Coffee break



NORWEGIAN CANCER SOCIETY



OSLO CANCER CLUSTER



The Research Council of Norway



European Observatory on Health Systems and Policies
MAKING SENSE OF THE EVIDENCE



Connecting PCM innovation to routine care in Norway

14.40 - 15.40 | Moderator: Florian Tille, the European Observatory on Health Systems and Policies

Framing the dialogue:

- **Trygve Ottersen**, Director General, Norwegian Medical Product Agency (TBC)
- **Jens Torup Østby**, Country Lead & Market Access Director Norway, BMS (TBC)

Guiding topics for discussion:

- *Leveraging PCM evidence into access pathways*
- *Implementing outcome-based managed entry framework for PCM*
- *Shared HTA assessment across countries*

The way forward

15.40 - 16.00 | Moderator: Florian Tille, the European Observatory on Health Systems and Policies

The policy dialogue will agree on **next steps** for improving connection between patient access to PCM and clinical trial set ups, and anchor follow-up work in **existing national platforms/partnerships**.



NORWEGIAN CANCER SOCIETY



OSLO CANCER
CLUSTER



The Research
Council of Norway



European
Observatory
on Health Systems and Policies
MAKING SENSE OF THE EVIDENCE



ECHoS